Intermittent androgen blockade in prostate cancer: Rationale and clinical experience

European Urology

Volumn 38, Issue 4, 2000, Pages 365-371

  Wolff, J M ^a   Tunn, U W ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Androgen blockade; Intermittent therapy; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; DNA; GROWTH FACTOR; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANEMIA; APOPTOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CASTRATION; DEPRESSION; DRUG INTERMITTENT THERAPY; GYNECOMASTIA; HUMAN; MALE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TESTIS;

EID: 0033760677     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020310     Document Type: Review

References (40)

1. Transplantation der Hoden
2. The results of double castration in hypertrophy of the prostate
3. The question of castration for enlarged prostate
4. Studies on prostatic cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
5. Overview over phase III trials on combined androgen treatment in patients with metastatic prostate cancer
6. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy
7. The endocrinology and treatment of prostate tumour progression
8. Effects of intermittent androgen suppression of androgen-dependent tumours: Apoptosis and serum-specific antigen
9. Hormonal control of growth and progression in tumours of Nb rats and theory of action
10. Successive waves of apoptosis in the rat after repeated withdrawal of testosterone stimulation
11. The prostate in eunuchs
12. Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer
13. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer
14. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
15. Animal models in the study of progression of prostate and breast cancers to androgen independency
16. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma
17. Experimental treatment of prostatic cancer by intermittent hormonal therapy
18. Serum PSA levels in mice bearing human prostate LNCaP tumours are determined by tumour volume and endocrine growth factors
19. Intermittent androgen suppression delays time to androgen-independent progression in the LNCaP prostate tumour model
20. Palliation by castration or by hormone administration
21. Pathological growth of androgen-sensitive tissues resulting from latent actions of steroid hormones
22. Comparison between continuous and intermittent administration of Estracyt in the treatment of carcinoma of the prostate
23. Intermittent endocrine therapy for advanced prostate cancer
24. Intermittent androgen suppression in treatment of prostate cancer. A preliminary report
25. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
26. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer
27. Current status of intermittent androgen suppression in the treatment of prostate cancer
28. Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience
29. A pilot study of intermittent androgen deprivation in advanced prostate cancer
30. A phase II study of intermittent androgen suppression in men with a rising serum PSA after radiation for localized prostate cancer
31. Intermittent androgen suppression in the management of prostate cancer
32. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer
33. Impact of intermittent androgen deprivation on quality of life
34. Efficacy and effect on quality of life of intermittent androgen deprivation for prostate cancer treatment
35. Phase III study of intermittent MAB versus continuous MAB International Cooperative Study
36. Intermittierende Androgendeprivation
37. Klinische Studien der AUO zur intermittierenden Androgenprivation beim Prostatakarzinom